Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

December 10, 2023

Preliminary Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

American Society of Hematology (ASH) Annual Meeting and Exposition 2024
CTCL LGL-L PTCL Solid Tumors
Read More
November 14, 2023

IRAK4 Degradation vs Inhibition

IRAK4 Program Background
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
November 13, 2023

Nature Medicine: IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial

Lindsay Ackerman, Gerard Acloque, Sandro Bacchelli, Howard Schwartz, Brian J. Feinstein, et al.
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
October 16, 2023

Development of KT-253, a highly potent and selective heterobifunctional MDM2 degrader, for the treatment of Acute Myeloid Leukemia

10th International MDM2 Workshop
Liquid Tumors Solid Tumors
Read More
October 14, 2023

The MDM2 degrader KTX-049 is highly potent in TP53 wild-type (p53 WT) Merkel cell carcinoma (MCC)

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.
Solid Tumors
Read More
August 16, 2023

Discovery of KT-474, a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases

American Chemical Society (ACS) Fall 2023 Meeting
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More
July 24, 2023

Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders

Gadiyar, V., Patel, G., Chen, J., Vigil, D., Ji, N., Campbell, V., Sharma, K., Shi, Y., Weiss, M., Birge, R., & Davra, V.
Read More
June 14, 2023

Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors

International Conference on Malignant Lymphoma (ICML) 2023
CTCL LGL-L PTCL Solid Tumors
Read More
June 6, 2023

Pulse Dosing of Potent and Selective Heterobifunctional MDM2 Degrader KT-253 Drives Tumor Regression and Demonstrates Differentiated Pharmacology Compared to p53/MDM2 Small Molecule Inhibitors

European Hematology Association (EHA) 2023 Hybrid Congress
Liquid Tumors
Read More
May 18, 2023

Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis

European Academy of Dermatology & Venereology (EADV) Symposium 2023
Atopic Dermatitis (AD) Hidradenitis Suppurativa (HS)
Read More